Illuminate Therapeutics is redefining cancer treatment with its first-in-class, spatially-directed RNAi therapeutics for difficult cancers, like head and neck squamous and glioblastoma.

Illuminate’s proprietary platform, LADDR, is the first to solve RNAi delivery hurdles by pairing RNAi-nanoparticle-conjugates with light or ultrasound activation only in tumor tissue, achieving multi-targeted, tumor-specific gene silencing to treat complex cancers. LADDR delivers potent tumor cell killing yet sparing healthy tissue with its unmatched spatial precision, finally unlocking the power of genetic medicine in cancers.